Prestige Consumer Healthcare (PBH) Peer Comparison
$48.70
$-1.09
(-2.19%)
As on 09-Sep-2026 16:00EDT
Market cap
$2,476 Mln
Revenue (TTM)
$1,105 Mln
P/E Ratio
14.6
P/B Ratio
1.3
Div. Yield
0 %
Edit
| Prestige Consumer Healthcare (PBH) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
2,476 | 14,631 | 12,066 | 12,237 | 10,826 |
Revenue ($ Mln) |
1,105 | 692 | 831 | 5,020 | 777 |
Net Profit ($ Mln) |
172.01 | -696.24 | 54.90 | -199.00 | -191.64 |
Net Margin (%) |
15.57 | -100.64 | 6.61 | -3.96 | -24.68 |
RoE (%) |
9.18 | -- | 8.11 | -3.03 | -223.36 |
Price to Earnings |
14.64 | -- | 248.04 | -- | -- |
Price-To-Book |
1.30 | 123.68 | 17.29 | 1.86 | 131.04 |
Income Statement ($ Mln)
| Prestige Consumer Healthcare (PBH) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
1,088.71 | 502.08 | 761.41 | 4,715.00 | 638.50 |
|
Cost of Revenue
|
514.07 | 28.27 | 12.98 | 2,665.00 | 47.48 |
|
Gross Profit
|
574.64 | 473.81 | 748.43 | 2,050.00 | 591.02 |
|
Operating Expenses
|
265.23 | 1,042.89 | 703.63 | 1,798.00 | 760.25 |
|
Operating Profit (EBIT)
|
309.41 | -569.09 | 44.80 | 252.00 | -169.24 |
|
Other Income
|
-- | -- | -- | -- | -- |
|
Profit before Tax
|
257.50 | -734.99 | 66.46 | -224.00 | -183.70 |
|
Provision for Tax
|
67.20 | 0.56 | -33.19 | 8.00 | -0.53 |
|
Profit after Tax (Net Income)
|
190.30 | -729.31 | 99.65 | -232.00 | -183.17 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Consolidated Profit
|
214.61 | -- | -- | -- | -- |
Liabilities ($ Mln)
| Prestige Consumer Healthcare (PBH) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
1,887.52 | -2,076.58 | 647.81 | 6,547.00 | 88.30 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Non-Current Liabilities
|
1,539.13 | 2,724.64 | 22.76 | 5,214.00 | 222.67 |
|
Current Liabilities
|
120.92 | 287.97 | 166.09 | 1,597.00 | 378.84 |
|
Total Liabilities
|
3,547.57 | 936.03 | 836.65 | 13,358.00 | 689.81 |
Assets ($ Mln)
| Prestige Consumer Healthcare (PBH) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
3,116.09 | 41.59 | 351.19 | 9,900.00 | 100.82 |
|
Current Assets
|
431.48 | 753.68 | 485.46 | 3,458.00 | 588.99 |
|
Total Assets
|
3,547.57 | 936.03 | 836.65 | 13,358.00 | 689.81 |
|
Total Debt*
|
1,045.43 | 2,728.72 | 6.11 | 4,017.00 | 241.30 |
|
Net Current Assets
|
310.56 | 509.78 | 319.38 | 1,861.00 | 210.15 |
Cashflow ($ Mln)
| Prestige Consumer Healthcare (PBH) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
257.63 | -445.91 | 142.00 | 560.00 | -93.41 |
|
Cash Flow from Investing Activities
|
-136.84 | -24.49 | 69.76 | -279.00 | -0.48 |
|
Cash from Financing Activities
|
-156.06 | 359.29 | -220.37 | -275.00 | 101.47 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Prestige Consumer Healthcare (PBH) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
6.55 | -159.44 | 14.87 | -2.21 | -63.21 |
|
ROE (%)
|
10.22 | 41.15 | 15.01 | -3.67 | -252.11 |
|
ROA (%)
|
5.48 | -78.62 | 11.88 | -1.79 | -29.11 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
17.48 | -145.26 | 13.09 | -4.92 | -28.69 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| Prestige Consumer Healthcare (PBH) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-0.04 | 1.26 | 0.13 | 0.06 | 0.66 |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
-11.32 | -36.12 | -28.68 | -168.64 | 36.22 |
|
EPS Growth (%)
|
-0.07 | -0.31 | -0.30 | -1.68 | 0.39 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| Prestige Consumer Healthcare (PBH) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
14.85 | -20.69 | 41.86 | -48.47 | -50.48 |
|
Price / Book Value
|
1.50 | -7.27 | 6.44 | 1.72 | 104.73 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
11.50 | -25.60 | 55.67 | 21.77 | -54.53 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Prestige Consumer Healthcare (PBH) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.55 | -1.31 | 0.01 | 0.61 | 2.73 |
|
Short term debt to equity ratio
|
0.01 | -0.01 | 0.00 | 0.01 | 0.83 |
|
Current Ratio
|
3.57 | 2.62 | 2.92 | 2.17 | 1.55 |
|
Quick Ratio
|
2.25 | 2.52 | 2.85 | 1.08 | 1.48 |
|
Interest Coverage
|
7.08 | -12.84 | -- | -0.02 | -27.02 |
Operating Efficiency Ratios
| Prestige Consumer Healthcare (PBH) | BridgeBio Pharma (BBIO) | Corcept Therapeutics (CORT) | Elanco Animal Health (ELAN) | Axsome Therapeutics (AXSM) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
17.63 | 27.77 | 7.85 | 19.94 | 35.16 |
|
Asset Turnover
|
0.31 | 0.54 | 0.91 | 0.36 | 1.01 |
|
Receivable days
|
64.79 | 52.44 | 28.27 | 70.73 | 104.82 |
|
Inventory Days
|
109.01 | 172.81 | 355.76 | 226.89 | 167.98 |
|
Payable days
|
14.82 | 296.14 | 785.55 | 45.50 | 529.03 |
|
Cash Conversion Cycle
|
158.97 | -70.89 | -401.52 | 252.12 | -256.23 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
